Insider Trading Arrangements |
3 Months Ended |
|---|---|
|
Sep. 30, 2026
shares
| |
| Trading Arrangements, by Individual | |
| Material Terms of Trading Arrangement | We describe the material terms of these Rule 10b5-1 Trading Plans below.
On August 7, 2026, Chris Wright, M.D., Ph.D., our Chief Medical Officer, adopted a Rule 10b5-1 Trading Plan providing for the sale of up to an aggregate of 60,000 shares of our common stock pursuant to the terms of such Rule 10b5-1 Trading Plan. Dr. Wright’s Rule 10b5-1 Trading Plan is active until , or earlier, if and when all transactions under the Rule 10b5-1 Trading Plan are completed. On July 30, 2026, Paul B. Bolno, M.D., MBA, our President and Chief Executive Officer, terminated a Rule 10b5-1 Trading Plan that was originally adopted on May 26, 2026. Dr. Bolno’s former Rule 10b5-1 Trading Plan provided for the sale of up to an aggregate of 2,924,270 shares of our common stock. No shares were sold under Dr. Bolno’s Rule 10b5-1 Trading Plan prior to its termination. |
| Paul B. Bolno [Member] | |
| Trading Arrangements, by Individual | |
| Name | Paul B. Bolno |
| Title | our President and Chief Executive Officer |
| Rule 10b5-1 Arrangement Terminated | true |
| Termination Date | July 30, 2026 |
| Aggregate Available | 2,924,270 |
| Chris Wright [Member] | |
| Trading Arrangements, by Individual | |
| Name | Chris Wright |
| Title | our Chief Medical Officer |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | August 7, 2026 |
| Arrangement Duration | 474 days |
| Aggregate Available | 60,000 |